Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
Information source: Roswell Park Cancer Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Essential Thrombocythemia; Polycythemia Vera; Primary Myelofibrosis
Intervention: Arsenic Trioxide (Drug); Ascorbic Acid (Dietary Supplement); Laboratory Biomarker Analysis (Other); Pharmacological Study (Other)
Phase: Phase 1
Status: Active, not recruiting
Sponsored by: Roswell Park Cancer Institute
Official(s) and/or principal investigator(s):
Eunice Wang, MD, Principal Investigator, Affiliation: Roswell Park Cancer Institute
This phase I trial studies the side effects and best dose of arsenic trioxide with or
without ascorbic acid in treating patients with myelofibrosis. Drugs used in chemotherapy,
such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving arsenic acid together with ascorbic acid may kill more cancer cells.
Official title: A Phase I Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults With Myelofibrosis
Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Adverse events, and their attribution throughout the study
Dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 3.0 (Stage 1)
Maximum tolerated dose (MTD), defined as the dose level at which 0 or 1 of 6 subjects experience DLT, and 2 of 3 or 2 of 6 experience DLT at the next higher dose level, assessed by the NCI CTC version 3.0 (Stage 1)
Change in absolute number of circulating CD34+ cells in the peripheral blood (Stage 2 only)
Change in JAK2/MPL (Stage 2 only)
Change in plasma levels of chemokines as measured by ELISA (Stage 2)
Change in plasma levels of cytokines as measured by ELISA (Stage 2)
Change in plasma levels of proteases as measured by enzyme-linked immunosorbent assay (ELISA) (Stage 2)
Disease response assessed using the IWG-MRT response criteria
I. To determine the safety and maximum tolerated dose of oral arsenic trioxide with or
without ascorbic acid in subjects with myelofibrosis.
I. To estimate the incidence, severity, and attribution of treatment-emergent adverse
II. To estimate the rate of complete or major clinical-hematological response from treatment
with arsenic trioxide and ascorbic acid in this subject population as measured by the
International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) response
III. To measure arsenic trioxide levels in the plasma of patients treated with and without
ascorbic acid on this protocol.
IV. To estimate the efficacy of arsenic trioxide with ascorbic acid in subjects with
myelofibrosis, as determined by a reduction in Janus kinase 2 (JAK2) V617F, JAK22T875N, and
mutations of the thrombopoietin receptor (MPL515L/K) allele frequency in peripheral blood
V. To examine the effect of treatment on biological markers of myeloproliferation, cytokine
production and hematopoietic stem cell mobilization. In particular, the following markers of
disease will be measured: cluster of differentiation (CD)34+ cell count in peripheral blood
measured by cytofluorimetry, plasma vascular endothelial growth factor (VEGF), transforming
growth factor-beta (TGF-B), stromal cell-derived factor-1 (SDF-1), neutrophil elastase
levels by commercial assays.
VI. To examine single nucleotide polymorphism (SNP) in the arsenic trioxide pathway in
subjects with myelofibrosis treated with arsenic trioxide and ascorbic acid.
OUTLINE: This is a dose-escalation study of arsenic trioxide.
Patients receive arsenic trioxide orally (PO) once daily (QD) in orange juice on days 1-21.
Patients may also receive ascorbic acid PO QD on days 1-21. Treatment repeats every 28 days
for up to 168 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 4
months for 1 year.
Minimum age: 19 Years.
Maximum age: N/A.
- Diagnosis of primary myelofibrosis, essential thrombocythemia related myelofibrosis,
or polycythemia vera related myelofibrosis requiring therapy, including:
- Those previously treated and relapsed or refractory
- Or, if newly diagnosed, with intermediate or high risk according to Lille
scoring system (adverse prognostic factors are: hemoglobin [Hb] < 10 g/dl, white
blood cell count [WBC] < 4 or > 30 x 10^9/L; risk group: 0 = low, 1 =
intermediate, 2 = high)
- Or with symptomatic splenomegaly (must be >= 23 cm by ultrasound in the
- Signed informed consent: patients must have signed consents for both the arsenic
trioxide with ascorbic acid protocol and for the hematologic malignancy procurement
protocol to be eligible to participate
- Patients must have been off any primary myelofibrosis (PMF)-directed experimental
therapy for 4 weeks prior to entering this study and have recovered from the toxic
effects (grade 0-1) of that therapy; treatment with hydroxyurea and erythropoietin
are permitted until study initiation
- Serum bilirubin levels =< 2 times the upper limit of the normal range for the
laboratory (ULN); higher levels are acceptable if these can be attributed by treating
physician to active hemolysis or ineffective erythropoiesis due to myelofibrosis
- Serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) levels =<
2 x ULN
- Serum creatinine levels =< 1. 5 x ULN
- Women of childbearing potential must have a negative serum or urine pregnancy test
prior to arsenic trioxide treatment and should be advised to avoid becoming pregnant
- Men must be advised to not father a child while receiving treatment with arsenic
- Both women of childbearing potential and men must practice effective methods of
contraception (those generally accepted as standard of care measures)
- Women of childbearing potential are women who are not menopausal for 12 months or who
have not undergone previous surgical sterilization
- If the subject is a woman of childbearing potential, she must use a medically
acceptable form of contraception during the study period and for 30 days thereafter
- If the subject is a man he must be surgically sterile or must use a medically
approved method of contraception for the duration of the study and for 60 days
following the last dose of arsenic trioxide
- Nursing and pregnant females; should a woman become pregnant or suspects she is
pregnant while participating in this study, she should inform her treating physician
- New York Heart Association (NYHA) grade II or greater congestive heart failure
- Unstable angina
- Corrected QT interval (QTc) > 450 in the presence of potassium >= 4 mEq/L and
magnesium >= 1. 7 mEq/L
- Eastern Cooperative Oncology Group (ECOG) > 2
- Major surgical procedure, open biopsy, or significant traumatic injury within 28
days, or anticipation of the need for major surgical procedure during the course of
- Biopsy or other minor surgical procedure, excluding placement of a vascular access
device or bone marrow biopsy, within 7 days prior to study enrollment
- Ongoing serious, non-healing wound, ulcer, or bone fracture
- Known hypersensitivity to any component of arsenic trioxide
Locations and Contacts
Roswell Park Cancer Institute, Buffalo, New York 14263, United States
Starting date: April 2010
Last updated: August 13, 2015